---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-016777"
form_type: "8-K"
ticker: "LPCN"
cik: "0001535955"
company_name: "Lipocine Inc."
filed_at: "2024-04-26T23:59:59+00:00"
generated_at: "2026-06-03T06:27:20.412561+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Lipocine enters new $10.6M ATM sales agreement with A.G.P., terminates prior Cantor facility

## Summary
- Entered ATM agreement with A.G.P./Alliance Global Partners to sell up to $10,616,169 of common stock at market prices.
- A.G.P. will receive 3.0% of aggregate gross proceeds from each sale under the agreement.
- Terminated prior ATM agreement with Cantor Fitzgerald & Co., effective immediately, to enter new facility.
- Either party may terminate the new agreement upon ten days' prior notice; no obligation to sell shares.

## SEC filing metadata
- accession: 0001493152-24-016777
- form_type: 8-K
- ticker: LPCN
- cik: 0001535955
- company_name: Lipocine Inc.
- filed_at: 2024-04-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 1.01, 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1535955/000149315224016777/0001493152-24-016777-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1535955/000149315224016777/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-016777
- JSON: https://secwatch.observer/filing/0001493152-24-016777.json
- Plain text: https://secwatch.observer/filing/0001493152-24-016777.txt

## Key facts
- Material Agreements
  Lipocine Inc. entered into ATM Agreement with A.G.P./Alliance Global Partners valued at up to $10,616,169 of Shares; 3.0% of aggregate gross proceeds per sale (effective 2024-04-26).
  - Action: entry
  - Agreement: atm program
  - Counterparty: A.G.P./Alliance Global Partners
  - Value: up to $10,616,169 of Shares; 3.0% of aggregate gross proceeds per sale
  - Effective: 2024-04-26
  source text: On April 26, 2024, Lipocine Inc. (the “Company”), entered into a sales agreement (the “ATM Agreement”) with A.G.P./Alliance Global Partners (“A.G.P.”), as sales agent, pursuant to which the Company may offer and sell shares of common stock, par value $0.0001 per share (the “Shares”), from time to time, in an at-the-market public offering.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1535955/000149315224016777/0001493152-24-016777-index.htm
- Material Agreements
  Lipocine Inc. terminated Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. valued at terminated effective immediately upon notice; waiver of notice period (effective 2024-04-24).
  - Action: termination
  - Agreement: atm program
  - Counterparty: Cantor Fitzgerald & Co.
  - Value: terminated effective immediately upon notice; waiver of notice period
  - Effective: 2024-04-24
  source text: On April 24, 2024, the Company provided notice to Cantor Fitzgerald & Co. (“Cantor”) of its election to terminate the Controlled Equity Offering SM Sales Agreement between them dated March 6, 2017 (the “Sales Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1535955/000149315224016777/0001493152-24-016777-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.